Could a monthly shot replace weekly diabetes injections?
NCT ID NCT07677891
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests whether people with type 2 diabetes can switch from a weekly injection of dulaglutide to a once-monthly shot called PG-102. The trial involves 60 adults whose blood sugar is well-controlled on dulaglutide. Researchers will compare blood sugar levels and safety over 32 weeks to see if the monthly option works just as well.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PG-102 (a GLP-1 and GLP-2 fusion protein)
What this could lead to
If successful, this could offer people with type 2 diabetes a convenient once-monthly injection instead of a weekly one, making blood sugar control easier to maintain.
What could go wrong
This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The new drug may not control blood sugar as well as the current weekly option, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••